The UK clinical research landscape continues to evolve, and this week the Medicines and Healthcare products Regulatory Agency (MHRA) published UK‑specific annotations to ICH Good Clinical Practice (GCP) E6(R3). These annotations are an important development for anyone involved in the design, conduct, oversight or support of clinical trials in the UK.
While ICH GCP E6(R3) provides an internationally agreed, principle‑based framework for clinical research, it does not replace national legislation. In the UK, clinical trials of investigational medicinal products remain governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended. The new annotations clarify how the revised ICH principles should be interpreted and applied within this existing legal framework.
For sponsors, investigators and trial teams, this guidance provides practical clarity on where flexibility exists and where UK law remains prescriptive. Training and internal procedures must now reflect these clarifications to ensure ongoing compliance and inspection readiness.
A key message reinforced by the annotations is that international guidance does not override UK legal obligations. Although E6(R3) introduces modern, risk‑proportionate approaches to trial oversight and documentation, sponsors retain ultimate responsibility under UK law. Tasks may be delegated, but accountability cannot be transferred.
The annotations also provide important clarification around safety reporting. In the UK, there is no legal requirement to routinely distribute individual suspected unexpected serious adverse reaction (SUSAR) reports to investigators or research ethics committees. Instead, reporting obligations focus on timely submission to the MHRA in line with UK regulatory processes. Understanding this distinction helps avoid unnecessary administrative burden at site level.
Consent and participant protection are another area where UK specificity matters. While ICH GCP refers to the use of a legally acceptable representative, UK law defines the role and hierarchy of legal representatives in detail. The annotations emphasise the need to follow the definitions set out in the Clinical Trials Regulations and, where applicable, the Mental Capacity Act. Applying generic international interpretations without reference to UK requirements may result in non‑compliance.
The management and retention of trial records is also addressed. ICH E6(R3) introduces concepts such as media‑neutral records and a focus on document essentiality. However, the annotations confirm that statutory UK retention periods remain unchanged. For example, the Trial Master File must still be retained for the period specified in UK legislation. Organisations should ensure that modern record‑keeping approaches do not inadvertently conflict with legal retention obligations.
Taken together, the MHRA’s UK‑specific annotations act as a bridge between updated international GCP principles and the UK regulatory environment. They provide valuable direction for applying E6(R3) in a way that is both proportionate and legally compliant.
This update also highlights why clinical trial training must be actively maintained. Generic or static GCP training may not address UK‑specific interpretations or recent regulatory developments, increasing the risk of misunderstanding and non‑compliance.
At Training Online 4U, we continually monitor regulatory publications and guidance updates, including the latest MHRA annotations to ICH GCP E6 (R3). Our UK‑focused training courses are regularly reviewed and updated to reflect current regulatory expectations, supporting practical application, inspection readiness and confident compliance across clinical research roles.
To find out more about our UK‑specific GCP and clinical trial training, visit www.trainingonline4u.com.
